(Q40210840)

18 September 2017

Hemozoin is a potent adjuvant for hemagglutinin split vaccine without pyrogenicity in ferrets (English)

1 reference

18 September 2017

1 reference

8

1 reference

18 September 2017

Motoyasu Onishi

1

0 references

Cevayir Coban

object named as

Cevayir Coban

7

0 references

author name string

Mitsutaka Kitano

2

1 reference

18 September 2017

Keiichi Taniguchi

3

1 reference

18 September 2017

Tomoyuki Homma

4

1 reference

18 September 2017

Masanori Kobayashi

5

1 reference

18 September 2017

Akihiko Sato

6

1 reference

18 September 2017

language of work or name

English

0 references

publication date

8 April 2014

1 reference

18 September 2017

1 reference

18 September 2017

32

1 reference

18 September 2017

25

1 reference

18 September 2017

3004-3009

1 reference

Theories on malarial pigment formation and quinoline action

18 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

Immunogenicity of whole-parasite vaccines against Plasmodium falciparum involves malarial hemozoin and host TLR9.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

Antibody response to influenza vaccination in the elderly: a quantitative review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

Adjuvants in influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

Progress in understanding adjuvant immunotoxicity mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

Estimation of the neuraminidase content of influenza viruses and split-product vaccines by immunochromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

The malarial metabolite hemozoin and its potential use as a vaccine adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

Silica Crystals and Aluminum Salts Regulate the Production of Prostaglandin in Macrophages via NALP3 Inflammasome-Independent Mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

Influenza virus pyrogenicity: central role of structural orientation of virion components and involvement of viral lipid and glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

Influenza vaccines for the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

Vaccine adjuvants revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

Malarial hemozoin is a Nalp3 inflammasome activating danger signal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

Pathogen recognition and development of particulate vaccines: does size matter?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.072

10.1016/J.VACCINE.2014.03.072

7 January 2021

Identifiers

DOI

1 reference

18 September 2017

1 reference